

Anders Rane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5026902/publications.pdf>

Version: 2024-02-01

123
papers

8,048
citations

47006

47
h-index

48315

88
g-index

126
all docs

126
docs citations

126
times ranked

6286
citing authors

#	ARTICLE	IF	CITATIONS
1	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	3
2	Effects of angiotensin II receptor blockers on serum levels of epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids in patients admitted to a cardiovascular center. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 887-894.	1.9	0
3	Tribute to Folke Sjöqvist, a Pioneer in Clinical Pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1127-1128.	4.7	0
4	Male Anabolic Androgenic Steroid Users with Personality Disorders Report More Aggressive Feelings, Suicidal Thoughts, and Criminality. <i>Medicina (Lithuania)</i> , 2020, 56, 265.	2.0	14
5	Improved infrastructure and support needed for paediatric clinical trials in Sweden. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 2740-2747.	1.5	2
6	Encouraging prospects for paediatric drug development in Europe. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 438-439.	1.5	0
7	Tardy development of safe medicines for children: a Nordic network offers new platform to reduce this inequity. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2019, 108, 992-993.	1.5	4
8	Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2019, 108, 1441-1446.	1.5	8
9	Pregnancy greatly affects the steroidal module of the Athlete Biological Passport. <i>Drug Testing and Analysis</i> , 2018, 10, 1070-1075.	2.6	12
10	Combined effect of telmisartan and fluvastatin on arachidonic acid metabolism in human liver microsomes. <i>Xenobiotica</i> , 2018, 48, 898-903.	1.1	1
11	Sensitivity of doping biomarkers after administration of a single dose testosterone gel. <i>Drug Testing and Analysis</i> , 2018, 10, 839-848.	2.6	35
12	Pregnancy-Induced Perturbation of Urinary Androgenic Steroid Disposition. <i>Journal of the Endocrine Society</i> , 2018, 2, 597-608.	0.2	2
13	Vitamin D receptor rs2228570 polymorphism is associated with LH levels in men exposed to anabolic androgenic steroids. <i>BMC Research Notes</i> , 2018, 11, 51.	1.4	4
14	Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant <sc>CYP</sc>2C9, <sc>CYP</sc>2J2 and Human Liver Microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 239-245.	2.5	14
15	Reply to "Multiple and Opposite Effects of Angiotensin II Receptor Blockers on the Bioavailability of Epoxyeicosatrienoic Acids". <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 215-216.	2.5	0
16	Discordant genotyping results using DNA isolated from anti-doping control urine samples. <i>Drug Testing and Analysis</i> , 2017, 9, 994-1000.	2.6	7
17	Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 1078-1085.	1.4	6
18	The Inhibitory Effect of Telmisartan on the Metabolism of Arachidonic Acid by CYP2C9 and CYP2C8: An <i>in Vitro</i> Study. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 1409-1415.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Recruitment to doping and help-seeking behavior of eight female AAS users. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2016, 11, 11.	2.2	38
20	Statin-induced myopathy in a usual care setting—a prospective observational study of gender differences. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1171-1176.	1.9	15
21	Low Vitamin D Levels and Genetic Polymorphism in the Vitamin D Receptor are Associated with Increased Risk of Statin-Induced Myopathy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 214-218.	2.5	27
22	The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 408-414.	2.5	3
23	Atypical excretion profile and GC/IRMS findings may last for nine months after a single dose of nandrolone decanoate. <i>Steroids</i> , 2016, 108, 105-111.	1.8	8
24	Statin-Induced Myopathy and Ubiquinone Levels in Serum — Results from a Prospective, Observational Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 133-136.	2.5	8
25	Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 261-266.	2.5	29
26	Dose-dependent testosterone sensitivity of the steroidal passport and GC-IRMS analysis in relation to the UGT2B17 deletion polymorphism. <i>Drug Testing and Analysis</i> , 2015, 7, 1063-1070.	2.6	46
27	Perturbation of the Hematopoietic Profile by Anabolic Androgenic Steroids. <i>Journal of Hormones</i> , 2014, 2014, 1-7.	0.2	11
28	CYP2C8 and CYP2C9 mRNA expression profile in the human fetus. <i>Frontiers in Genetics</i> , 2014, 5, 58.	2.3	13
29	Effects of different doses of testosterone on gonadotropins, 25-hydroxyvitamin D3, and blood lipids in healthy men. <i>Substance Abuse and Rehabilitation</i> , 2014, 5, 121.	4.8	19
30	PDE7B is involved in nandrolone decanoate hydrolysis in liver cytosol and its transcription is up-regulated by androgens in HepG2. <i>Frontiers in Pharmacology</i> , 2014, 5, 132.	3.5	5
31	Prenatal expression of thioredoxin reductase 1 (TRXR1) and microsomal glutathione transferase 1 (MGST1) in humans. <i>FEBS Open Bio</i> , 2014, 4, 886-891.	2.3	17
32	Seeking Improved Global Child Health: Progress Toward Millennium Development Goal 4. <i>Paediatric Drugs</i> , 2014, 16, 101-103.	3.1	3
33	A supraphysiological dose of testosterone induces nitric oxide production and oxidative stress. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1049-1054.	1.8	47
34	Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism. <i>Frontiers in Endocrinology</i> , 2013, 4, 75.	3.5	12
35	Institutional Profile: Karolinska Institutet. <i>Pharmacogenomics</i> , 2012, 13, 1887-1891.	1.3	2
36	Single dose testosterone increases total cholesterol levels and induces the expression of HMG CoA Reductase. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2012, 7, 12.	2.2	26

#	ARTICLE	IF	CITATIONS
37	DNA methylation dynamics in the hepatic CYP3A4 gene promoter. <i>Biochimie</i> , 2012, 94, 2338-2344.	2.6	54
38	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. <i>Thrombosis and Haemostasis</i> , 2012, 107, 232-240.	3.4	62
39	Androgens and doping tests: genetic variation and pitfalls. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 3-15.	2.4	34
40	Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2011, 127, 295-300.	2.5	48
41	Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 325-332.	1.5	24
42	CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia. <i>Journal of Microbiology and Biotechnology</i> , 2011, 21, 93-99.	2.1	17
43	Pharmacogenetics of Anticoagulants. <i>Human Genomics and Proteomics</i> , 2010, 2, 754919.	1.5	15
44	Dual use of anabolic-androgenic steroids and narcotics in Sweden. <i>Drug and Alcohol Dependence</i> , 2010, 109, 144-146.	3.2	34
45	Genetic variation in androgen disposition: implications in clinical medicine including testosterone abuse. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 731-744.	3.3	13
46	A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose. <i>PLoS Genetics</i> , 2009, 5, e1000433.	3.5	554
47	Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 365-375.	1.9	189
48	SFINX—a drug-drug interaction database designed for clinical decision support systems. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 627-633.	1.9	124
49	Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. <i>Steroids</i> , 2009, 74, 365-368.	1.8	38
50	The largest prospective warfarin-treated cohort supports genetic forecasting. <i>Blood</i> , 2009, 113, 784-792.	1.4	490
51	Incidence and predictors of severe bleeding during warfarin treatment. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 151-159.	2.1	48
52	Use of doping agents, particularly anabolic steroids, in sports and society. <i>Lancet</i> , The, 2008, 371, 1872-1882.	13.7	297
53	Doping Test Results Dependent on Genotype of Uridine Diphospho-Glucuronosyl Transferase 2B17, the Major Enzyme for Testosterone Glucuronidation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2500-2506.	3.6	163
54	Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 477-485.	1.5	49

#	ARTICLE	IF	CITATIONS
55	Sex Steroid Levels and Cortical Bone Size in Young Men Are Associated with a Uridine Diphosphate Glucuronosyltransferase 2B7 Polymorphism (H268Y). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3697-3704.	3.6	24
56	The Uridine Diphosphate Glucuronosyltransferase 2B15 D85Y and 2B17 Deletion Polymorphisms Predict the Glucuronidation Pattern of Androgens and Fat Mass in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4878-4882.	3.6	58
57	Regulation and expression of human CYP7B1 in prostate: Overexpression of CYP7B1 during progression of prostatic adenocarcinoma. <i>Prostate</i> , 2007, 67, 1439-1446.	2.3	41
58	EXPRESSION OF CYP3A ISOFORMS AND P-GLYCOPROTEIN IN HUMAN STOMACH, JEJUNUM AND ILEUM. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 1138-1144.	1.9	82
59	Association of the cytochrome P450 1A2*1F polymorphism with clozapine response in schizophrenic patients. <i>FASEB Journal</i> , 2007, 21, A196.	0.5	4
60	Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 54-61.	4.0	103
61	Large Differences in Testosterone Excretion in Korean and Swedish Men Are Strongly Associated with a UDP-Glucuronosyl Transferase 2B17 Polymorphism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 687-693.	3.6	258
62	Effects of the Antifungals Voriconazole and Fluconazole on the Pharmacokinetics of S-(+)- and R-(-)-Ibuprofen. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1967-1972.	3.2	47
63	Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 540-550.	4.7	58
64	Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 54-60.	2.4	182
65	Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 493-499.	1.9	54
66	THE IMPACT OF CYP2C9 GENETICS AND ORAL CONTRACEPTIVES ON CYTOCHROME P450 2C9 PHENOTYPE. <i>Drug Metabolism and Disposition</i> , 2004, 32, 484-489.	3.3	47
67	Identification of cytochromes P 450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 173-182.	1.9	69
68	Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 779-783.	1.9	40
69	The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 571-577.	1.9	99
70	Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. <i>Biochemical and Biophysical Research Communications</i> , 2002, 299, 25-28.	2.1	133
71	The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 504-510.	2.4	50
72	Independent patterns of cytochrome P 450 gene expression in liver and blood in patients with suspected liver disease. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 403-409.	1.9	36

#	ARTICLE	IF	CITATIONS
73	Caffeine Metabolism and the Risk of Spontaneous Abortion of Normal Karyotype Fetuses. <i>Obstetrics and Gynecology</i> , 2001, 98, 1059-1066.	2.4	29
74	Messenger Ribonucleic Acid Levels of Steroid 5 α -Reductase 2 in Human Prostate Predict the Enzyme Activity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 855-858.	3.6	27
75	Survey of unlicensed and off label drug use in paediatric wards in European countries. <i>BMJ: British Medical Journal</i> , 2000, 320, 79-82.	2.3	622
76	Caffeine Intake and the Risk of First-Trimester Spontaneous Abortion. <i>New England Journal of Medicine</i> , 2000, 343, 1839-1845.	27.0	241
77	Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 397-402.	2.4	37
78	Prostate cancer associated with CYP17 genotype. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 635-640.	5.7	85
79	Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 333-340.	5.7	98
80	Phenotyping of Drug Metabolism in Infants and Children: Potentials and Problems. <i>Pediatrics</i> , 1999, 104, 640-643.	2.1	24
81	Selective effects of somatostatin analogs on human drug-metabolizing enzymes*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 150-159.	4.7	13
82	Endocrine and adrenergic pharmacological intervention in diseases of the prostate. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 329-337.	2.4	6
83	Induction of CYP2D6 in pregnancy*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 400-407.	4.7	207
84	Comparison Between One and Three Years of Treatment in Uncomplicated Childhood Epilepsy: A Prospective Study. I. Outcome in Different Seizure Types. <i>Epilepsia</i> , 1996, 37, 822-832.	5.1	38
85	Tricyclic Antidepressants Inhibit Opioid Receptor Binding in Human Brain and Hepatic Morphine Glucuronidation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1994, 75, 23-27.	0.0	36
86	Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. <i>Biochemical Pharmacology</i> , 1994, 48, 59-64.	4.4	179
87	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993, 44, 61-67.	2.5	49
88	Glucuronidation of Morphine and some Drug Oxidation Reactions in Liver Microsomes from Pregnant and Non-Pregnant Rhesus Monkeys. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1991, 69, 78-80.	0.0	2
89	Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P-450IID1. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 27-35.	4.7	85
90	The Rhesus Monkey as a Model for Studies of Pregnancy Induced Changes in Metoprolol Metabolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1990, 66, 32-36.	0.0	6

#	ARTICLE	IF	CITATIONS
91	Development of the Glucuronyltransferase and Sulphotransferase towards 2-Naphthol in Human Fetus. <i>Developmental Pharmacology and Therapeutics</i> , 1990, 14, 108-114.	0.2	58
92	Therapeutic Drug Monitoring of Anticonvulsants. <i>Clinical Pharmacokinetics</i> , 1990, 18, 318-328.	3.5	49
93	The enantioselective glucuronidation of morphine in rats and humans. <i>Biochemical Pharmacology</i> , 1989, 38, 3273-3280.	4.4	83
94	Glutathione S-transferase in humans: development and tissue distribution. <i>Archives of Toxicology</i> , 1988, 61, 265-269.	4.2	56
95	Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam. <i>British Journal of Pharmacology</i> , 1988, 94, 864-870.	5.4	20
96	Human brain metabolism of morphine and naloxone. <i>Pain</i> , 1988, 35, 121-127.	4.2	80
97	Valproate in the Treatment of Absence Epilepsy in Children: A Study of Dose-Response Relationships. <i>Epilepsia</i> , 1988, 29, 548-552.	5.1	29
98	Acetyltransferase in Humans: Development and Tissue Distribution. <i>Pharmacology</i> , 1986, 32, 283-291.	2.2	143
99	Pregnancy-induced increase in metoprolol metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 688-692.	4.7	119
100	A Prospective Controlled trial of Metoprolol-Hydralazine Treatment in Hypertension during Pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1985, 64, 505-510.	2.8	53
101	Prednisolone excretion in human milk. <i>Journal of Pediatrics</i> , 1985, 106, 1008-1011.	1.8	217
102	Comparative Determination of Sulfonamide Concentration in Serum by Chemical and Microbiological Assay. <i>Scandinavian Journal of Infectious Diseases</i> , 1984, 16, 309-314.	1.5	5
103	Atenolol and Metoprolol. A Comparison of Their Excretion into Human Breast Milk. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1984, 63, 65-69.	2.8	38
104	Renal Glucuronidation of Morphine in the Human Foetus. <i>Acta Pharmacologica Et Toxicologica</i> , 1982, 50, 155-160.	0.0	20
105	Relation of naproxen kinetics to effect on platelet prostaglandin release in men and dysmenorrheic women. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 29, 168-173.	4.7	20
106	Additive Clinical Effect of Indomethacin Suppositories During Salicylate Therapy in Rheumatoid Patients. <i>Scandinavian Journal of Rheumatology</i> , 1981, 10, 69-75.	1.1	6
107	Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 83-88.	4.7	130
108	Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 23, 658-668.	4.7	136

#	ARTICLE	IF	CITATIONS
109	Clinical Pharmacokinetics in Infants and Children. <i>Clinical Pharmacokinetics</i> , 1976, 1, 2-24.	3.5	119
110	Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 276-283.	4.7	87
111	Diphenylhydantoin Binding to Proteins in Plasma and Its Dependence on Free Fatty Acid and Bilirubin Concentration in Dogs and Newborn Infants. <i>Pediatric Research</i> , 1975, 9, 26-30.	2.3	53
112	N-oxidation of a tertiary amine (N,N-dimethylaniline) by human fetal liver microsomes. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 15, 32-38.	4.7	21
113	Plasma disappearance of transplacentally transferred diphenylhydantoin in the newborn studied by mass fragmentography. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 15, 39-45.	4.7	66
114	Metabolism of Desmethylinipramine in Human Foetal and Adult Liver Microsomes. <i>Acta Pharmacologica Et Toxicologica</i> , 1974, 34, 58-64.	0.0	11
115	Oxidative Drug Metabolism in the Perinatal Rabbit Liver and Placenta: A Biochemical and Morphologic Study. <i>Xenobiotica</i> , 1973, 3, 37-48.	1.1	26
116	Formation of a 16,17-trans-glycolic metabolite from a 16-dehydro-androgen in human fetal liver microsomes. <i>Clinical Pharmacology and Therapeutics</i> , 1973, 14, 833-839.	4.7	18
117	Drugs and fetal metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1973, 14, 666-672.	4.7	44
118	Drug Metabolism in the Human Fetus and Newborn Infant. <i>Pediatric Clinics of North America</i> , 1972, 19, 37-49.	1.8	44
119	The liver microsomal monooxygenase system in the human fetus: Distribution in different centrifugal fractions. <i>Clinical Pharmacology and Therapeutics</i> , 1972, 13, 652-662.	4.7	36
120	Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. <i>Journal of Pediatrics</i> , 1971, 78, 877-882.	1.8	101
121	PLASMA PROTEIN BINDING, PLASMA CONCENTRATIONS, AND EFFECTS OF DIPHENYLHYDANTOIN IN MAN. <i>Annals of the New York Academy of Sciences</i> , 1971, 179, 723-728.	3.8	39
122	Developmental Aspects of Pharmacokinetics. <i>Acta Pharmacologica Et Toxicologica</i> , 1971, 29, 240-249.	0.0	4
123	Plasma protein binding of diphenylhydantoin in man; Interaction with other drugs and the effect of temperature and plasma dilution. <i>Clinical Pharmacology and Therapeutics</i> , 1970, 11, 846-855.	4.7	240